Portal thrombosis and steatosis after preoperative chemotherapy with FOLFIRI-bevacizumab for colorectal liver metastases

Matteo Donadon, Jean Nicolas Vauthey, Evelyne M. Loyer, Chusilp Charnsangavej, Eddie K. Abdalla

Research output: Contribution to journalArticle


In order to discuss the role of preoperative chemotherapy for colorectal liver metastases, which is used frequently before hepatic resection, even in patients with resectable disease at presentation, we herein report the development of two complications, partial portal vein thrombosis and hepatic steatosis with lobular inflammation, during the course of preoperative chemotherapy with FOLFIRI plus bevacizumab for colorectal liver metastases, which recognition led to timely discontinuation of chemotherapy as well as a change in the surgical strategy to resect the tumors and the damaged liver through advanced techniques. We conclude that duration of treatment and drug doses and combinations may impact the development of chemotherapy-induced liver injury. Surgeons and medical oncologists must work together to devise safe, rational, and oncologically appropriate treatments for patients with multiple colorectal liver metastases, and to improve the understanding of the pathogenesis of chemotherapy-induced liver injury.

Original languageEnglish
Pages (from-to)6556-6558
Number of pages3
JournalWorld Journal of Gastroenterology
Issue number40
Publication statusPublished - Oct 28 2006



  • Chemotherapy
  • Colorectal liver metastases
  • Resection

ASJC Scopus subject areas

  • Gastroenterology

Cite this